Clinical trials: Omega 3 Fatty Acids
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Weight Gain, Healthy Subjects
Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition
Background: Rates of obesity have increased dramatically in recent decades, and researchers are investigating how changes in diets and physical activity have contributed to this increase.
- Conditions
- Weight Gain, Healthy Subjects, Obesity, Women
- Trial name
- NCT01251887
- Testing
- Linoleic Acid, Docosahexaenoic Acid, Eicosapentaenoic Acid
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Diabetes Mellitus, Type 1, Hypoglycemia
Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients
The investigator propose to test the safety and efficacy of a regimen that combines Omega-3 Fatty Acids and Vitamin D in a design that considers timing and duration of administration in relation to their effects and predicted…
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Diabetes Mellitus, Diabetes, Autoimmune
- Trial name
- POSEIDON (NCT03406897)
- Testing
- Cholecalciferol, Omega 3 fatty acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Rodolfo Alejandro